Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
Figure 7.
Clinicopathological characteristics of breast cancer
| Variables | N | % | |
|---|---|---|---|
| Side | left | 66 | 44.9 |
| right | 81 | 55.1 | |
| Histological type | lobular | 18 | 12.4 |
| ductal | 123 | 84.8 | |
| other | 4 | 2.8 | |
| Histological grade | HG1 | 17 | 11.9 |
| HG2 | 73 | 51 | |
| HG3 | 53 | 37.1 | |
| Nuclear grade | NG1 | 17 | 15.2 |
| NG2 | 64 | 57.1 | |
| NG3 | 31 | 27.7 | |
| Mitotic index | grade 1 | 19 | 42.2 |
| grade 2 | 20 | 44.4 | |
| grade 3 | 6 | 13.3 | |
| Tumor necrosis | absent | 26 | 21.7 |
| present | 94 | 78.3 | |
| Desmoplasia | low | 17 | 16.3 |
| medium | 55 | 52.9 | |
| high | 32 | 30.8 | |
| Periductal elastosis | low | 19 | 20.0 |
| medium | 20 | 44.4 | |
| high | 16 | 35.6 | |
| Perineural invasion | absent | 101 | 68.7 |
| present | 46 | 31.3 | |
| Lymphatic invasion | absent | 72 | 48.9 |
| present | 75 | 51.1 | |
| Vascular invasion | absent | 113 | 76.9 |
| present | 34 | 23.1 | |
| HER2 | negative | 115 | 79.3 |
| positive | 30 | 20.7 | |
| Ki67 | low | 30 | 20..9 |
| medium | 42 | 29.4 | |
| high | 71 | 49.7 | |
| Molecular subtypes | Lum A | 30 | 20.4 |
| Lum B | 76 | 51.7 | |
| HER2 + | 19 | 12.9 | |
| TNBC | 22 | 15 | |
| T status | T1 | 48 | 35.8 |
| T2 | 64 | 47.8 | |
| T3 | 9 | 6.7 | |
| T4 | 13 | 9.7 | |
| N status | N0 | 50 | 37.3 |
| N1 | 48 | 35.8 | |
| N2 | 19 | 14.2 | |
| N3 | 17 | 12.7 | |
Association between GLB1 expression in IBC and examined clinicopathological characteristics
| Variables | GLB1 cut off 27,5% | Chi-Square | p | ||
|---|---|---|---|---|---|
| Mononuclear infiltrate | absent | 2 (6,5%) | 2 (3,2%) | 3,892 | 0,273 |
| low | 10 (32,3%) | 33 (53,2%) | |||
| medium | 14 (45,2%) | 21 (33,9%) | |||
| high | 5 (16,1%) | 6 (9,7%) | |||
| Stromal fibroblasts | negative | 4 (22,2%) | 13 (17,3%) | 0,020 | 0,887 |
| positive | 14 (77,8%) | 62 (82,7%) | |||
| Histological type | lobular | 4 (10,8%) | 14 (13,0%) | 0,120 | 0,942 |
| ductal | 32 (86,5%) | 91 (84,3%) | |||
| other | 1 (2,7%) | 3 (2,8%) | |||
| Histological grade | HG1 | 2 (5,3%) | 15 (14,3%) | 10,016 | 0,007 |
| HG2 | 14 (36,8%) | 59 (56,2%) | |||
| HG3 | 22 (57,9%) | 31 (29,5%) | |||
| Nuclear grade | NG1 | 2 (6,7%) | 15 (18,3%) | 8,080 | 0,018 |
| NG2 | 14 (46,7%) | 50 (61,0%) | |||
| NG3 | 14 (46,7%) | 17 (20,7) | |||
| Tumor necrosis | absent | 5 (16,7%) | 21 (23,3%) | 0,262 | 0,609 |
| present | 25 (83,3%) | 69 (76,7) | |||
| Perineural invasion | absent | 27 (71,1%) | 74 (67,9%) | 0,025 | 0,874 |
| present | 11 (28,9%) | 35 (32,1%) | |||
| Lymphatic invasion | absent | 14 (36,8%) | 58 (53,2%) | 2,402 | 0,121 |
| present | 24 (63,2%) | 51 (46,8%) | |||
| Vascular invasion | absent | 31 (81,6%) | 82 (75,2%) | 0,639 | 0,424 |
| present | 7 (18,4%) | 27 (24,8%) | |||
| Molecular subtypes | Lum A | 5 (13,2%) | 25 (22,9%) | 67,563 | 0,000 |
| Lum B | 12 (31,6%) | 64 (58,7%) | |||
| HER2 + | 0 (0,0%) | 19 (17,4%) | |||
| TNBC | 21 (55,3%) | 1 (0,9%) | |||
| HER2 | negative | 36 (94,7%) | 79 (73,%) | 6,249 | 0,012 |
| positive | 2 (5,3%) | 28 (26,2%) | |||
| Ki67 | low | 7 (20,0%) | 23 (21,3%) | 0,433 | 0,805 |
| medium | 9 (25,7%) | 33 (30,6%) | |||
| high | 19 (54,3%) | 52 (48,1%) | |||
| T status | T1 | 10 (28,6%) | 38 (38,4%) | 2,457 | 0,507 |
| T2 | 18 (51,4%) | 46 (46,5%) | |||
| T3 | 4 (11,4%) | 5 (5,1%) | |||
| T4 | 3 (8,6%) | 10 (10,1%) | |||
| N status | N0 | 9 (25,0%) | 41 (41,8%) | 4,862 | 0,182 |
| N1 | 13 (36,1%) | 35 (35,7%) | |||
| N2 | 8 (22,2%) | 11 (11,2%) | |||
| N3 | 6 (16,7%) | 11 (11,2%) | |||